Baxter recieves warning letter from FDA

Share this article:
The Office of Compliance and Biologics Quality (OCBQ) in the FDA's Center for Biologics Evaluation and Research (CBER) has sent a warning letter to Baxter regarding the company's promotional material for Tisseel general surgery brochure.

The OCBQ claims that the presentation, brochure and sell sheet are false or misleading because these materials, among other things, overstate the efficacy of Tisseel and make unsubstantiated claims of superiority for Tisseel over other conventional hemostatic agents. The OCBQ asked Baxter to cease the dissemination of “violative” promo material for Tisseel.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?